Insight Molecular Diagnostics Inc. IMDX
1.97 USD +0.31 (+18.67%)
Regular-session close
1.94 -0.03 -1.52%
After hours · Nov 20, 7:53 PM ET
1.62 Day range 2.01
1.59 52-week range 7.50
- YTD
- -73.73%
- 1 year
- -67.55%
News
benzinga.com Lake Street Maintains Buy on Insight Molecular, Lowers Price Target to $9 Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and lowers the price target from $12 to $9.
benzinga.com Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the…
globenewswire.com iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study NASHVILLE, Tenn., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that the first several patients have been enrolled in its GALACTIC…benzinga.com Stephens & Co. Reiterates Equal-Weight on Insight Molecular, Maintains $4 Price Target Stephens & Co. analyst Mason Carrico reiterates Insight Molecular (NASDAQ:IMDX) with a Equal-Weight and maintains $4 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 21.2% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.6 million. As per the press release, Q3…
globenewswire.com Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Aytu BioPharma (NASDAQ:AYTU) shares rose 45.0% to $2.64 during Tuesday's pre-market session. The market value of their outstanding shares is at $19.7 million. The company's, Q1 earnings came…
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
marketbeat.com What Oncocyte (IMDX) Said on Its Q3 Earnings Call Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration's request for more information about its GraftAssureDx kidney…
globenewswire.com IMDx Reports Third Quarter 2026 Results and Provides Corporate Update NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third…
globenewswire.com Insight Molecular Diagnostics Announces Proposed Public Offering NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an…
